Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for Cardamyst
Milestone Pharmaceuticals announced the FDA accepted their New Drug Application for Cardamyst (etripamil) nasal spray, intended for paroxysmal supraventricular tachycardia (PSVT) management. The PDUFA target date is set for 10 months after the acceptance date. Cardamyst aims to provide a new, convenient treatment option for PSVT patients, potentially allowing self-management without medical supervision.
Highlighted Terms
Related News
Milestone Pharmaceuticals announced the FDA accepted their New Drug Application for Cardamyst (etripamil) nasal spray, intended for paroxysmal supraventricular tachycardia (PSVT) management. The PDUFA target date is set for 10 months after the acceptance date. Cardamyst aims to provide a new, convenient treatment option for PSVT patients, potentially allowing self-management without medical supervision.